Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells.
A unique class of IFN-producing killer dendritic cells (IKDC) resembling natural killer cells has been defined that can recognize and lyse tumor cells through a tumor necrosis factor-related apoptosis-inducing ligand-dependent mechanism. IKDC may mediate the host-dependent antitumor activity of Gleevec/STI571 and other therapeutics that can inhibit the c-kit tyrosine kinase. IKDC represent an important new component of the innate immune system responding to cancer.
Ullrich
Evelyn
E
Institut National de la Santé et de la Recherche Médicale U805, Faculté de Médecine Kremlin Bicêtre, Villejuif, France.
Bonmort
Mathieu
M
Mignot
Grégoire
G
Chaput
Nathalie
N
Taieb
Julien
J
Ménard
Cédric
C
Viaud
Sophie
S
Tursz
Thomas
T
Kroemer
Guido
G
Zitvogel
Laurence
L
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001549:Benzamides; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology*; D000068877:Imatinib Mesylate; D007167:Immunotherapy / Q000379:methods; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology*; D051379:Mice; D009374:Neoplasms, Experimental / Q000276:immunology* / Q000628:therapy; D010879:Piperazines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D007371:Interferon-gamma; D000068877:Imatinib Mesylate